Cancers are highly complex diseases that are characterized by not only the overgrowth of
malignant cells but also an altered immune response. The inhibition and reprogramming of …

Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) are the preferential
options for advanced non-small cell lung cancer (NSCLC) patients harboring EGFR …

Hypoxia is a known feature of solid tumors and a critical promoter of tumor hallmarks.
Hypoxia influences tumor immunity in a way favoring immune evasion and resistance …

Simple Summary Osimertinib, a third-generation epidermal growth factor receptor (EGFR)
tyrosine kinase inhibitor, is currently indicated as first-line therapy in patients with non-small …

According to global cancer data, lung cancer was the leading cause of cancer‑related death
in 2020. With the diversification of treatment strategies, the survival outcomes of patients with …

Almost 17% of Western patients affected by non-small cell lung cancer (NSCLC) have an
activating epidermal growth factor receptor (EGFR) gene mutation. Del19 and L858R are the …

Simple Summary Resistance to tyrosine kinase inhibitors (TKIs) of the epidermal growth
factor receptor (EGFR) in advanced mutant non-small cell lung cancer (NSCLC) constitutes …

Simple Summary Lung cancer is still one of the most commonly diagnosed and deadliest
cancers in the world. Its diagnosis at an early stage is highly necessary and will improve the …

Resistance mechanisms to osimertinib and emerging therapeuti... : Current Opinion in
Oncology Resistance mechanisms to osimertinib and emerging therapeutic strategies in …

Background Data on the use of immune checkpoint inhibitors (ICIs) in advanced non-small
cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) mutation …